Ads
related to: acute leukemia survival rate- Find Support & Resources
Learn About Support & Resources
For An R/R ALL Rx Treatment Option
- Dosing & Administration
Find Dosing & Modifications For
An R/R B-Cell ALL Rx Option.
- How To Order R/R ALL Rx
Find Specialty Distributors
For An R/R ALL Rx Treatment Option
- Relapsed/Refractory ALL
Learn About Relapsed/Refractory
ALL On An Official HCP Site
- Find Support & Resources
Search results
Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
Zacks via Yahoo Finance· 2 hours agoThe approval was based on an encouraging response rate and duration of response data from the phase...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 4 days agoAML is a cancer of the blood and bone marrow and is the most common type of acute leukemia in adults. SENTI-202, a potential first-in-class Logic Gated ...
Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to...
Nature· 3 days agoIn contrast to B-cell precursor acute lymphoblastic leukemia (ALL), molecular subgroups are less well defined in T-lineage ALL. Comprehensive studies on ...
Patients Over 80 Still Benefit From Treatment for AML Blood Cancer
Alaska Superstation· 3 days agoSeniors over 80 with acute myeloid leukemia can safely and effectively take the standard targeted...
Earnings call: Aptose Biosciences targets AML treatment with tuspetinib By Investing.com
Investing.com· 2 days agoAptose Biosciences (NASDAQ:APTO) has focused its efforts on developing tuspetinib as part of a novel...
Earnings call: Bio-Path Holdings reports promising Q1 2024 results By Investing.com
Investing.com· 2 days agoBio-Path Holdings (NASDAQ: NASDAQ:BPTH), a biotechnology company focused on developing therapeutic...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 3 days ago– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients; successfully bridged responding TP53m AML patients to hematopoietic cell transplantation – – SL
Aptose Reports Results for the First Quarter 2024
Digital Journal· 3 days agoTUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed ...